Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Introduction: The incidence of hearing loss after treatment with carboplatin-based chemotherapy in nasopharyngeal carcinoma (NPC) patients were evaluated, and relationships of loss with host factors, treatment-related factors were investigated. Objective: To evaluate the effect of giving a carboplatin chemotherapy regimen for 6 times chemotherapy (serial chemotherapy) on hearing function in patients with nasopharyngeal carcinoma. The incidence of hearing loss after treatment with carboplatin-based chemotherapy in nasopharyngeal carcinoma (NPC) patients were evaluated, and relationships of loss with host factors, treatment-related factors were investigated. Method: Thirty NPC patients were treated with carboplatin chemotherapy from 2015 to 2017 were analyzed. Pure tone audiometry and Distortion Product of Otoacoustic emission (DPOAE) were performed during the follow-up period, with a median time of 36 months, ranging from 24 to 36 months. Correlation of SNHL at frequencies (pure tone average, 0.5-8 kHz) with a series of factors was analyzed. Results: Among 30 participant (60 ears), using the Wilcoxon test, the mean threshold after series III was significant (p=0,000) and the mean of after series VI and significant (p= 0,000). The relationship between DPOAE results and pure tone audiometry was also carried out in the early stages of series III. Kaplan Meier's survival analysis improvement from post-III series (6 weeks) of participants who survived as many as 23 participants (76.67%) and in the post-chemotherapy evaluation of VI series (15 weeks) participants who survived as many as 8 participants. Bivariate statistical analysis using the Spearman non-parametric correlation test, there was a significant relationship between the mean dose and the decrease in the hearing threshold. p=0.00 (<0.01). Conclusion: For NPC patients treated with carboplatin chemotherapy, There was an effect on the hearing function of the administration of carboplatin chemotherapy regimen for 6 series chemotherapy in patients with nasopharyngeal carcinoma.
Introduction: The incidence of hearing loss after treatment with carboplatin-based chemotherapy in nasopharyngeal carcinoma (NPC) patients were evaluated, and relationships of loss with host factors, treatment-related factors were investigated. Objective: To evaluate the effect of giving a carboplatin chemotherapy regimen for 6 times chemotherapy (serial chemotherapy) on hearing function in patients with nasopharyngeal carcinoma. The incidence of hearing loss after treatment with carboplatin-based chemotherapy in nasopharyngeal carcinoma (NPC) patients were evaluated, and relationships of loss with host factors, treatment-related factors were investigated. Method: Thirty NPC patients were treated with carboplatin chemotherapy from 2015 to 2017 were analyzed. Pure tone audiometry and Distortion Product of Otoacoustic emission (DPOAE) were performed during the follow-up period, with a median time of 36 months, ranging from 24 to 36 months. Correlation of SNHL at frequencies (pure tone average, 0.5-8 kHz) with a series of factors was analyzed. Results: Among 30 participant (60 ears), using the Wilcoxon test, the mean threshold after series III was significant (p=0,000) and the mean of after series VI and significant (p= 0,000). The relationship between DPOAE results and pure tone audiometry was also carried out in the early stages of series III. Kaplan Meier's survival analysis improvement from post-III series (6 weeks) of participants who survived as many as 23 participants (76.67%) and in the post-chemotherapy evaluation of VI series (15 weeks) participants who survived as many as 8 participants. Bivariate statistical analysis using the Spearman non-parametric correlation test, there was a significant relationship between the mean dose and the decrease in the hearing threshold. p=0.00 (<0.01). Conclusion: For NPC patients treated with carboplatin chemotherapy, There was an effect on the hearing function of the administration of carboplatin chemotherapy regimen for 6 series chemotherapy in patients with nasopharyngeal carcinoma.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.